Expanding Access to CAR T-Cell therapy: Outpatient Management & the Role of remote Monitoring
The landscape of cancer treatment is evolving rapidly, particularly with the increasing availability of innovative therapies like CAR T-cell therapy. Traditionally confined to major academic medical centers, these powerful treatments are now expanding into community oncology practices, offering hope to more patients. A recent study, ZUMA-24, demonstrates the feasibility of outpatient administration of axicabtagene ciloleucel (axi-cel) for relapsed or refractory large B-cell lymphoma, marking a significant step forward in accessibility.
This shift isn’t without it’s considerations. Let’s explore the key findings of ZUMA-24, the challenges of moving CAR T-cell therapy into the community setting, adn how emerging technologies like remote patient monitoring are paving the way for safer, more efficient care.
ZUMA-24: A Landmark Study in Outpatient CAR T-Cell Therapy
Published in the American Journal of Cancer Research in 2025, the ZUMA-24 trial enrolled patients between August 2022 and March 2024. The primary analysis revealed that outpatient axi-cel administration is indeed feasible in a multicenter surroundings.
Here’s what the study highlighted:
* Feasibility: Outpatient administration proved viable across multiple sites.
* Manageable Toxicity: Prophylactic corticosteroids and early intervention strategies, including hospitalization when needed, resulted in relatively low rates of high-grade toxicities.
* Reduced Hospital Stay: Patients experienced shorter hospital stays compared to previous trials utilizing inpatient administration of axi-cel. This translates to more efficient healthcare resource utilization and alleviates pressure on hospital capacity.
These findings are particularly encouraging as they suggest that you, as a patient, may have access to this perhaps life-saving therapy closer to home.
Navigating the Challenges of Community-Based CAR T-Cell Therapy
While the ZUMA-24 results are promising, expanding CAR T-cell therapy to community practices requires careful consideration. One key challenge lies in managing potential adverse events (AEs) outside the traditional hospital setting.
A significant aspect of accomplished outpatient treatment relies on caregivers being vigilant for early signs of AEs, sometimes even before the patient recognizes them. However, this reliance on caregivers can be a point of concern.
Furthermore, recent changes by the FDA regarding Risk Evaluation and Mitigation Strategies (REMS) have prompted discussion among payers. Bryan Loy, MD, MBA, of Humana, raised a valid point: the removal of dual certification requirements could lead payers to question the safety and efficacy of outpatient delivery.
The Rise of Remote Patient Monitoring: A Critical Component
To address these challenges, community oncology practices are increasingly turning to remote patient monitoring (RPM). This technology allows clinicians to track your response to treatment remotely, providing an extra layer of safety and support.
here’s how RPM is being implemented:
* Wearable Devices: Some practices are utilizing wearable devices to monitor body temperature, serving as an early warning system for potential AEs.
* Continuous Data Collection: RPM enables continuous data collection, allowing for proactive intervention if any concerning trends emerge.
* CMS Reimbursement: The Centers for Medicare & medicaid Services (CMS) has begun reimbursing community oncology practices for RPM,making it more accessible.
The ZUMA-24 study investigated the use of a wearable device, finding it predictive of AEs. While the sample size was limited and some false positives/negatives occurred,the potential is clear. Other studies have demonstrated adherence rates above 79% with wearable devices, indicating strong patient acceptance.
What This Means for You
The evolution of CAR T-cell therapy administration signifies a positive trend for cancer patients. You can expect:
* Increased Access: More opportunities to receive cutting-edge treatment closer to home.
* Potentially Lower Costs: Shorter hospital stays can contribute to reduced overall treatment costs.
* Enhanced Safety: Proactive monitoring and early intervention strategies minimize the risk of severe complications.
As community oncology practices continue to adopt and refine these approaches, CAR T-cell therapy will become increasingly integrated into standard cancer care.
References:
- Leslie LA,baird JH,Flinn IW,et al. Outpatient axicabtagene ciloleucel for relapsed/refractory large